Maria Baggstrom.jpg

Maria Quintos Baggstrom, MD

Associate Professor
Department of Medicine
Oncology Division
Medical Oncology

Clinical Interests

  • Thoracic oncology
  • Clinical trial methodology
  • Medical education


  • 314-362-5817 (office)
  • 314-362-3895 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8056
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110


Involvement in clinical trials:

Served as Principal Investigator of a national, multicenter clinical trial of AT-101 in small cell lung cancer supported by National Cancer Institute Cancer Therapeutics Evaluation Program, 2007- 2011. Published 2011.

Served as junior national co-Principal Investigator/Chair of a national, multicenter clinical trial of sunitinib in non-small cell lung cancer through the Cancer and Leukemia Group B (CALGB)/Alliance oncology cooperative group, 2008 – present. Published May 2017.

Member, Washington University Siteman Cancer Center, 2005 – present. Serve currently as Principal Investigator and Co-Investigator on several clinical trials in thoracic oncology.

Site principal investigator:

  • CALGB 30504 (NCT00453154): Combination Cisplatin, Etoposide with or without Maintenance Sunitinib Malate (IND 74019 - NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study. (Cooperative Group). Published 2015.
  • CALGB CIRB 30610 (NCT00632853): Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also receiving Cisplatin and Etoposide. (Cooperative Group). Ongoing.
  • CALGB 30801 (NCT 01041781): A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer. (Cooperative Group). Published May 2017.
  • 201105207 (NCT00921310): A Phase I/II Trial of Temsirolimus and Pemetrexed in Recurrent/Refractory Non-small Cell Lung Cancer (NSCLC). (Institutional, Primary). Published January 2016.
  • Several industry sponsored trials in chemotherapeutic agents in the treatment of nonsmall cell and small cell lung cancer.